Pre-Conference Day
Tuesday - 23 April, 2024
Predictive BMx Journey from Concept to Commercialization: Starting with the End in Mind
9am - 1pm
Join Roche for a morning of blended learning, with presentations, panel discussions, and group debate, covering key topics including:
- Commericialisation
- CDx Development - IVDR, Multi-Stage/Pan Tumor Approach
- Early BMx Discovery
Afternoon Thought Leadership Engager with Foundation Medicine
2pm - 4pm
Advancing Novel Biomarkers from Discovery through Clinical Development
Learn about innovative new biomarkers, like Foundation Medicine’s HRD signature and ctDNA tumor fraction, and how your essential diagnostics partner can support early biomarker discovery efforts through global clinical trial development and regulatory milestones
Advancing AAV Therapies: Diagnostic Strategies for Development & Approval
5pm - 7pm
Join Quest Diagnostics for an evening session that offers a strategic advantage in understanding and mitigating immunogenicity, thereby expediting the development of robust, market-ready gene therapies.
- Understand the role of immunogenicity in the success of gene therapies
- Identify the critical importance of AAV antibody testing
- Acquire actionable insights from Quest's leading-edge approach to navigating these challenges
*Attendance subject to availability & approval